Viking Therapeutics Q2 2024 Earnings Report

Reported financial results for the second quarter of 2024 and provided a corporate update.

Key Takeaways

Viking Therapeutics reported a net loss of $22.3 million, or $0.20 per share, for the three months ended June 30, 2024. The company's cash, cash equivalents, and short-term investments totaled $942 million as of June 30, 2024. The company is advancing VK2735 to Phase 3 for obesity and plans to initiate an oral VK2735 Phase 2 study in obesity in 4Q24.

VK2735 to advance to Phase 3 for obesity; End-of-Phase 2 meeting planned for 2H24.

Oral VK2735 Phase 2 study in obesity expected to begin 4Q24.

Positive Biopsy Results From VK2809 Reported in June; End-of-Phase 2 Meeting in NASH/MASH Planned for 4Q24.

Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24.

Previous year: -$0.19

+5.3%

R&D Expenses

$23.8M